A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer

Inclusion Criteria:

* Confirmation of non-myeloid cancer (myeloproliferative disorders will be excluded).
* Hemoglobin concentration ≤ 11.0 g/dL.
* Age ≥ 18 years.
* Karnofsky performance status ≥ 60%.
* Anemia predominantly due to cancer or chemotherapy.
* Serum creatinine concentration ≤ 2.0 mg/dL.
* Total serum bilirubin ≤ 1.5 times the upper limit of normal.
* Nutritional status adequate to provide vitamin B12 and folate within the normal limits.
* Capacity to complete the web-based functional status, symptom and quality of life assessments.
* Ability to give informed consent.

Exclusion Criteria:

* Untreated symptomatic primary or metastatic cancer involving the central nervous system.
* History of clinically significant iron deficiency.
* Greater than two red blood cell transfusions within 2 weeks of registration or any red blood cell transfusion within 7 days of registration.
* Received epoetin alfa or darbepoetin alfa therapy within 3 weeks prior to randomization.
* History of a seizure disorder.
* Unstable angina, congestive heart failure (New York Heart Association \> class II or known ejection fraction \< 40%) or uncontrolled cardiac arrhythmias.
* Uncontrolled hypertension defined as a diastolic blood pressure \> 100 mmHg.
* Clinical evidence of active infection or inflammatory diseases such as rheumatoid arthritis. Subjects with active rheumatoid arthritis are excluded.
* Known positive test for human immunodeficiency virus infection.
* Known primary hematological disorder which could cause anemia such as sickle cell anemia.
* Pregnant or breast-feeding.
* Not using adequate contraception if of childbearing potential.
* Known hypersensitivity to any recombinant mammalian-derived product.